367 related articles for article (PubMed ID: 22471524)
21. Psychotropic Polypharmacy Among Children and Youth Receiving Medicaid, 2012-2015.
Lohr WD; Creel L; Feygin Y; Stevenson M; Smith MJ; Myers J; Woods C; Liu G; Davis DW
J Manag Care Spec Pharm; 2018 Aug; 24(8):736-744. PubMed ID: 30058983
[TBL] [Abstract][Full Text] [Related]
22. Prevalence, Time Trends, and Utilization Patterns of Psychotropic Polypharmacy Among Pediatric Medicaid Beneficiaries, 1999-2010.
Soria Saucedo R; Liu X; Hincapie-Castillo JM; Zambrano D; Bussing R; Winterstein AG
Psychiatr Serv; 2018 Aug; 69(8):919-926. PubMed ID: 29879872
[TBL] [Abstract][Full Text] [Related]
23. Incarceration and psychotropic drug use by youth.
Cuellar AE; Kelleher KJ; Kataoka S; Adelsheim S; Cocozza JJ
Arch Pediatr Adolesc Med; 2008 Mar; 162(3):219-24. PubMed ID: 18316658
[TBL] [Abstract][Full Text] [Related]
24. Patterns of cervical cancer screening, diagnosis, and follow-up treatment in a state Medicaid fee-for-service population.
Nadpara PA; Madhavan SS; Khanna R; Smith M; Miller LA
Popul Health Manag; 2012 Dec; 15(6):362-71. PubMed ID: 22788858
[TBL] [Abstract][Full Text] [Related]
25. Psychotropic medication trends among children and adolescents with autism spectrum disorder in the Medicaid program.
Schubart JR; Camacho F; Leslie D
Autism; 2014 Aug; 18(6):631-7. PubMed ID: 24165274
[TBL] [Abstract][Full Text] [Related]
26. Use of HIV and psychotropic medications among persons with serious mental illness and HIV/AIDS.
Lee S; Rothbard AB; Noll E; Blank MB
Adm Policy Ment Health; 2011 Sep; 38(5):335-44. PubMed ID: 20976619
[TBL] [Abstract][Full Text] [Related]
27. Effects of a limiting Medicaid drug-reimbursement benefits on the use of psychotropic agents and acute mental health services by patients with schizophrenia.
Soumerai SB; McLaughlin TJ; Ross-Degnan D; Casteris CS; Bollini P
N Engl J Med; 1994 Sep; 331(10):650-5. PubMed ID: 8052275
[TBL] [Abstract][Full Text] [Related]
28. Overuse of psychotropic medications among children and adolescents with autism spectrum disorders: perspective from a developing country.
Memari AH; Ziaee V; Beygi S; Moshayedi P; Mirfazeli FS
Res Dev Disabil; 2012; 33(2):563-9. PubMed ID: 22119705
[TBL] [Abstract][Full Text] [Related]
29. Patients with obsessive-compulsive disorder vs depression have comparable health care costs: a retrospective claims analysis of Florida Medicaid enrollees.
Hankin CS; Koran L; Sheehan DV; Hollander E; Culpepper L; Black DW; Knispel J; Dunn J; Dougherty DD; Bronstone A; Wang Z
Ann Clin Psychiatry; 2011 Nov; 23(4):285-96. PubMed ID: 22073386
[TBL] [Abstract][Full Text] [Related]
30. Multiple psychotropic pharmacotherapy among child and adolescent enrollees in Connecticut Medicaid managed care.
Martin A; Van Hoof T; Stubbe D; Sherwin T; Scahill L
Psychiatr Serv; 2003 Jan; 54(1):72-7. PubMed ID: 12509670
[TBL] [Abstract][Full Text] [Related]
31. Impact of a Medicaid copayment policy on prescription drug and health services utilization in a fee-for-service Medicaid population.
Hartung DM; Carlson MJ; Kraemer DF; Haxby DG; Ketchum KL; Greenlick MR
Med Care; 2008 Jun; 46(6):565-72. PubMed ID: 18520310
[TBL] [Abstract][Full Text] [Related]
32. Trends in psychotropic medication costs for children and adolescents, 1997-2000.
Martin A; Leslie D
Arch Pediatr Adolesc Med; 2003 Oct; 157(10):997-1004. PubMed ID: 14557161
[TBL] [Abstract][Full Text] [Related]
33. Medicaid managed care: are academic medical centers penalized by attracting patients with high-cost conditions?
Heisler M; DeMonner SM; Billi JE; Hayward RA
Am J Manag Care; 2003 Jan; 9(1):19-29. PubMed ID: 12549812
[TBL] [Abstract][Full Text] [Related]
34. Medicaid expenditures on psychotropic medications for maltreated children: a study of 36 States.
Raghavan R; Brown DS; Allaire BT; Garfield LD; Ross RE
Psychiatr Serv; 2014 Dec; 65(12):1445-51. PubMed ID: 25178250
[TBL] [Abstract][Full Text] [Related]
35. Medicaid policy changes in mental health care and their effect on mental health outcomes.
Cuellar AE; Markowitz S
Health Econ Policy Law; 2007 Jan; 2(Pt 1):23-49. PubMed ID: 18634670
[TBL] [Abstract][Full Text] [Related]
36. Psychotropic and anticonvulsant drugs in subjects with autism: prevalence and patterns of use.
Aman MG; Van Bourgondien ME; Wolford PL; Sarphare G
J Am Acad Child Adolesc Psychiatry; 1995 Dec; 34(12):1672-81. PubMed ID: 8543539
[TBL] [Abstract][Full Text] [Related]
37. The implementation of managed behavioral healthcare in Colorado and the effects on older Medicaid beneficiaries.
Kaskie B; Wallace N; Kang S; Bloom J
J Ment Health Policy Econ; 2006 Mar; 9(1):15-24. PubMed ID: 16733268
[TBL] [Abstract][Full Text] [Related]
38. Medicaid expenditures on psychotropic medications for children in the child welfare system.
Raghavan R; Brown DS; Thompson H; Ettner SL; Clements LM; Key W
J Child Adolesc Psychopharmacol; 2012 Jun; 22(3):182-9. PubMed ID: 22537361
[TBL] [Abstract][Full Text] [Related]
39. [Review of psychopharmacological treatments in adolescents and adults with autistic disorders].
Baghdadli A; Gonnier V; Aussilloux C
Encephale; 2002; 28(3 Pt 1):248-54. PubMed ID: 12091786
[TBL] [Abstract][Full Text] [Related]
40. Prevalence of psychotropic drug use in nursing homes for the aged in Quebec and in the French-speaking area of Switzerland.
Gobert M; D'hoore W
Int J Geriatr Psychiatry; 2005 Aug; 20(8):712-21. PubMed ID: 16035123
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
